The rapidly increasing number of multidrug-resistant tuberculosis (MDR-TB) cases worldwide underlines the necessity for the rational use of key second-line drugs such as kanamycin. In this study, we determined the prevalence of, and risk factors associated with, kanamycin-resistant tuberculosis (TB) in 309 Hospital, Beijing, China, with the aim of providing information for better case management in order to minimize further development of extensively drug-resistant TB (XDR-TB). Drug susceptibility testing results and clinical data were retrospectively analysed for hospitalized TB patients for whom such data were available in 309 Hospital for the period 1997-2009. Univariate and multivariate analyses were used to determine the risk factors associated with kanamycin-resistant TB. During 1997During -20094 %) of 3843 tested Mycobacterium tuberculosis isolates from hospitalized TB patients were kanamycin-resistant. The increasing trend of resistance to kanamycin was reversed since 2000. The independent risk factors associated with kanamycin-resistant TB included living in urban areas [adjusted odds ratio (OR)51.89], being retreated for repeat cases (adjusted OR51.60), being smear-positive for acid-fast bacilli at admission to the hospital (adjusted OR51.39), having ofloxacin-resistant (adjusted OR51.61) or para-aminosalicylic acid-resistant TB (adjusted OR51.47), having MDR-TB (adjusted OR55.10), having MDR-TB plus ofloxacin resistance (adjusted OR54.27) and having poly-resistant TB (adjusted OR53.94). The remaining rate of kanamycin resistance is still high despite the reversal of the increasing trend during the past decade. Surveillance of kanamycin resistance, especially among high-risk populations, should be continued to closely monitor trends so that appropriate action can be taken. XDR-TB cases (Shah et al., 2008; Abubakar et al., 2009; Zhao et al., 2009; Liu et al., 2011a) .
INTRODUCTION
According to the 2010 WHO report, the global estimated number of multidrug-resistant tuberculosis (MDR-TB) cases reached 440 000 in 2008, India and China together carrying nearly 50 % of the global burden. The number of countries reporting at least one case of extensively drugresistant tuberculosis (XDR-TB) had risen to 58 by January 2010. The number of MDR-TB cases that caused death was estimated to be 150 000 in 2008 (WHO, 2010a) . The latest nationwide baseline survey for tuberculosis (TB) drug resistance, carried out in China from 2007 to 2008, showed that 8.32 % of pulmonary TB patients in China suffered from MDR-TB and 0.68 % suffered from XDR-TB (WHO, 2010b) . These cases of highly drug-resistant TB are more difficult to treat and have poorer clinical outcomes compared to other TB cases as the standard first-line drug regimens are ineffective against most of these strains (Chiang et al., 2010; Chan & Iseman, 2008) . Injectable drugs such as kanamycin, amikacin and capreomycin are the key second-line drugs for the treatment of MDR-TB cases. The rapid increase in the number of MDR-TB cases in recent years further underlines the need for more intensive surveillance for susceptibility to these important second-line drugs to minimize further development of IP: 54.70.40.11 On: Tue, 26 Feb 2019 19:19:27 prevalence of resistance to fluoroquinolones among TB isolates from patients (Huang et al., 2005; Xu et al., 2009; Liu et al., 2011b) but such information for kanamycin has been largely lacking. We therefore conducted this retrospective study to assess the prevalence of kanamycin resistant TB among hospitalized TB patients in 309 Hospital, Beijing, China, for the period 1997-2009. We also sought to identify the risk factors associated with kanamycin resistance among hospitalized TB patients with the aim of improving case management in order to minimize the occurrence of kanamycin resistance in TB as well as the prevalence of XDR-TB. We noticed that after a significant increasing trend during 1997-2000, the rate of kanamycin resistance exhibited a decreasing trend during 2000-2009. In addition, except for some previously reported risk factors associated with drug-resistant TB, the present study further revealed that having ofloxacin-or para-aminosalicylic acid-resistant TB, having MDR-TB plus ofloxacin resistance, and having poly-resistant TB were also independently associated with the prevalence of kanamycin-resistant TB.
METHODS
Setting and patients. In this study, we included 3843 TB patients hospitalized in 309 Hospital, Beijing, China, between January 1997 and December 2009 who were culture-positive for TB and had drug susceptibility testing (DST) results available for the evaluation of the prevalence of kanamycin resistance. Further to this, we analysed information on the socio-demographic background and clinical characteristics of 3127 patients, including 439 patients with kanamycin-resistant TB and 2688 patients with kanamycin-susceptible TB, whose medical records were available, with the aim of determining the risk factors associated with kanamycin-resistant TB among hospitalized TB patients. Although the notification rate of cases of pulmonary TB in Beijing was reported to be lower than that of the national level (China Tuberculosis Control Collaboration, 2004) , there are a large number of TB patients from other provinces seeking treatment for TB in Beijing. 309 Hospital, which has a 244bed TB centre, is the only TB referral hospital in the urban area of Beijing city and is one of the major TB referral hospitals in China. The TB patients are either self-referred (46.1 %, 1442/3127) or referred by general practitioners from other hospitals or community clinics in Beijing and other provinces in China (53.9 %, 1685/3127). Generally, a large proportion of those patients who were referred to 309 Hospital from other hospitals and clinics were retreatment cases (61.0 %, 1028/ 1685) and had MDR-TB (32.8 %, 553/1685) or had serious underlying diseases, such as chronic obstructive pulmonary disease, hypertension or abnormal liver function (34.1 %, 574/1685).
Bacteriological examination and drug susceptibility testing.
Specimens were routinely collected from confirmed or suspected TB cases. Smear microscopy for acid-fast bacilli was performed and assessed by Ziehl-Neelsen staining. The specimens were further decontaminated and neutralized according to the manufacturer's instruction before being cultured using the BACTEC 460 system or BACTEC MGIT 960 system. Identification of Mycobacterium tuberculosis was performed by using p-nitrobenzoic acid and thiophene carboxylic acid hydrazine resistance tests as well as IS6110-based PCR (Eisenach et al., 1990) . DST was performed using the proportion method with Löwenstein-Jensen medium (the medium containing the drugs was produced in the lab before 2009 and was purchased from BaSO DIAGNOSTICS after 2009). The concentrations of the drugs used were as follows (mg ml 21 ): isoniazid (1), rifampicin (50), ethambutol (5), streptomycin (10), pyrazinamide (50), ofloxacin (2), levofloxacin (2), kanamycin (10) or aminosalicylate (1). Periodic external quality assessment of the performance of the DST was conducted by the Tuberculosis Reference Laboratory (TRL) at the Beijing Research Institute for Tuberculosis Control. All drugs were obtained from Sigma.
Definitions. New TB cases were defined as TB cases without a history of TB treatment or those who had received ,30 days of anti-TB treatment prior to the study. Retreated TB cases were defined as TB cases who had previously received at least 30 days of anti-TB treatment at any time during their lives (WHO, 2003) . Monoresistant TB was defined as resistance to a single first-line anti-TB drug. Poly-resistant TB was defined as resistance to two or more of the first-line anti-TB drugs, but not to either isoniazid or rifampicin. MDR-TB was defined as resistance to at least both isoniazid and rifampicin. XDR-TB was defined as resistance to at least isoniazid and rifampicin, plus resistance to any one of the fluoroquinolone drugs and to at least one of the three injectable second-line drugs (i.e. kanamycin, amikacin or capreomycin) (CDC, 2006; Crofton et al., 1997; WHO, 2006) . Statistical analysis. Data were analysed using the SPSS software package (version 15.0). Pearson's chi-squared (x 2 ) test was used to compare categorical variables. Trends in the prevalence of cases of kanamycin-resistant TB over the specified periods were examined using x 2 linear trend analysis. Univariate and multivariate analyses were used to determine the risk factors associated with kanamycinresistant TB. All potential risk factors were included in a logistic regression model for multivariate analysis and were eliminated using a backward stepwise selection method using a P-value threshold of 0.2 as a criterion for the variables to remain in the model. Mantel-Haenszel odds ratios (ORs), 95 % confidence intervals (CIs) and corresponding P-values were reported. A P-value of ,0.05 was considered to be statistically significant.
Ethical approval. The study was approved by the ethics committee of 309 Hospital.
RESULTS

Prevalence of kanamycin resistance and characteristics of the study subjects
From January 1997 to December 2009, 5512 TB patients, 2311 of which were new cases and 3201 of which were retreatment cases, received in-patient treatment in the TB centre of 309 Hospital. Of the 5512 non-duplicate samples, 3918 (71.1 %) were culture-positive for M. tuberculosis and were subjected to DST. Seventy-five patients were further excluded as a result of non-viable specimens or contaminated cultures. Of the remaining 3843 (69.7 %) isolates, 553 (14.4 %) were identified as being kanamycin-resistant. The prevalences of kanamycin resistance in new cases and retreated cases were 10.8 % (179/1653) and 17.1 % (374/ 2190), respectively. The prevalence of kanamycin resistance among total cases, new cases and retreatment cases increased significantly from 12.4, 9.3 and 14.9 %, respectively, in 1997; reaching their peaks in 2000 with prevalences of 49.5, 30.4 and 55.4 %, respectively (P,0.001 overall); and then declining to 6.9, 6.0 and 7.6 %, respectively, by 2009 (P,0.001 for all) (Fig. 1) . In addition, a total of 3127 patients, including 439 of the 553 kanamycin-resistant and 2688 of the 3290 kanamycin-susceptible patients, whose medical records were available were included in further assessment of the risk factors associated with kanamycin resistance. We compared characteristics including sex, age and treatment history for patients who were included and excluded from the study population and found no significant differences between them (data not shown).
Out of the 5512 patients tested for TB, three were found to be HIV-positive, but all of the 3127 patients who were included in the final analysis were HIV-negative. 
Anti-TB drug susceptibility patterns of the study subjects
Information on anti-TB drug susceptibility patterns is given in Table 2 . Among the five first-line anti-TB drugs, the rates of resistance to isoniazid (50.3 %) and rifampicin (47.1 %) were the highest, while the rate of resistance to pyrazinamide (23.1 %) was the lowest. The rates of resistance to the second-line drugs ofloxacin and para-aminosalicylic acid were 16.1 and 22.5 %, respectively. The rates of MDR-TB, MDR-TB plus ofloxacin resistance and poly-resistant TB 
DISCUSSION
A relatively higher rate of kanamycin resistance in cases of TB was documented in this study compared to studies from other regions. According to a study from India, kanamycin-resistant TB showed a prevalence of 6.5 % (184/ 2816) (Paramasivan et al., 2010) . Another study conducted in a Thailand hospital showed that 5.1 % of 99 MDR-TB isolates were kanamycin-resistant (Prammananan et al., 2005) . While the kanamycin resistance rate from this study was close to that from another hospital-based survey conducted in Beijing (15.5 %, 150/967) (Wang et al., 2010) , it was much higher than that (2.34 %, 92/3929) from the nationwide baseline survey in China (WHO, 2010a, b) . A few possible explanations for the high rates of kanamycinresistant TB seen in this study have been identified. First, kanamycin has been widely used by general clinicians for the treatment of infections other than TB in China. Second, kanamycin has been one of the key second-line drugs for treating TB in China for the past 30 years. Third, while non-compliance may contribute to resistance in some cases, the improper use of the drugs may lead to increased resistance. Fourth, there may be an on-going transmission of drug-resistant strains in Beijing as suggested by a study conducted in Shanghai . The much higher rate of kanamycin resistance that was observed in this hospital-based study compared with the nationwide survey has one specific explanation in that the percentage of retreatment cases (57.2 % versus 22.7 %) and MDR-TB cases (30.7 % versus 8.32 %) were much higher in this study, and these characteristics were shown to put the patients at a higher risk of developing further resistance to second-line anti-TB drugs such as kanamycin (Kliiman & Altraja, 2009; Suárez-García et al., 2009 ).
There are a number of possible explanations for the rapid increase in kanamycin resistance during 1997-2000 as shown in this study. First, progress on the control of TB had been slow in China before 2000. WHO recommended a directly observed treatment short-course strategy (DOTS), which was shown to help reduce drug-resistant TB cases (Xianyi et al., 2002) but was not widely implemented in China before 2000 (WHO, 2000) . Second, the increased prevalence of cases of kanamycin-resistant TB could be partly explained by the rapid increase in MDR-TB cases in China during that period, since having MDR-TB was shown to be associated with further risk of developing drug-resistant TB (Dye et al., 2002; Espinal et al., 2001) . Third, since cross-resistance between kanamycin and amikacin (a synthetic analogue of kanamycin) was reported to be high (Via et al., 2010) , the increased use of amikacin for TB treatment since the late 1990s in China could also have partly contributed to the high rate of resistance to kanamycin. (Wang et al., 2007) .
This study also helps to elucidate risk factors for kanamycin resistance among TB patients. In addition to some common risk factors observed previously for drug-resistant TB, such as previous history of anti-TB treatment (Suárez-García et al., 2009; Vashakidze et al., 2009) , living in an urban or densely populated area (Huong et al., 2006; Vashakidze et al., 2009) , being smear-positive for acid-fast bacilli at admission (Shah et al., 2008) , and having MDR-TB (Huang et al., 2005; Paramasivan et al., 2010) , we further revealed that having ofloxacin-or para-aminosalicylic acidresistant TB, having MDR-TB plus ofloxacin resistance and having poly-resistant TB were also independently associated with kanamycin-resistant TB. These phenomena could be explained by the fact that fluoroquinolones (such as ofloxacin and levofloxacin) and para-aminosalicylic acid have been more frequently prescribed for treating repeat cases and suspected MDR-and poly-resistant TB cases. A study has shown that resistance to amikacin and kanamycin is associated with unfavourable treatment outcome among MDR-and XDR-TB patients (Migliori et al., 2008) , suggesting an urgent need to advise the medical community on the rational use of these life-saving drugs for the treatment of the most difficult TB cases.
This study had a few limitations. First, the conclusions of this study apply mainly to TB referral hospitals in China, and generalizations with regard to other settings should be made with caution. Second, we did not include the information for some variables such as DST patterns on treatment initiation and drug use history because of the unavailability of consistent representative data. Third, the absence of drug-resistance test results for other injectable drugs could have biased the results, but since the crossresistance between kanamycin and other injectable drugs, especially amikacin, was high, this bias should be minimal. Fourth, the sampling bias caused by lack of testing for kanamycin resistance in cases of TB for some patients could lead to under-reporting of kanamycin-resistant TB during certain time windows.
In conclusion, the data from this study suggest that surveillance of kanamycin resistance in TB should be continued in order to closely monitor trends so that appropriate action can be taken. Furthermore, empirical regimens for the retreatment of patients are recommended to include cycloserine along with capreomycin as the injectable agent in similar settings in China and elsewhere.
